Effectdossier · gearchiveerd kwartaal
ALLO
Allogene Therapeutics, Inc. · Healthcare · Biotechnology
16Gevolgde houders
0Δ houders
74.87MGehouden aandelen
$92.84MGerapporteerde waarde
+1Nieuwe posities
−1Uitstappen
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +1.2% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -4 | 183.62M | $382.24M | +6 | −10 |
| Q1 2026 | 84 | +8 | 106.47M | $259.25M | +11 | −3 |
| Q4 2025 | 76 | +2 | 91.09M | $124.76M | +2 | — |
| Q3 2025 | 16 | 0 | 74.87M | $92.84M | +1 | −1 |
| Q2 2025 | 13 | 0 | 69.68M | $78.74M | — | — |
| Q1 2025 | 10 | +1 | 41.70M | $60.89M | +2 | −1 |
| Q4 2024 | 9 | -2 | 35.46M | $75.54M | — | −2 |
| Q3 2024 | 10 | 0 | 29.49M | $82.58M | — | — |
| Q2 2024 | 10 | — | 28.78M | $67.06M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 17.51M | -2.1% | $21.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 13.97M | +36.3% | $17.32M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 13.97M | +36.3% | $17.32M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passief) | 9.02M | +9.2% | $11.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passief) | 9.02M | +9.2% | $11.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passief) | 9.02M | +9.2% | $11.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | PRIMECAP Management ✦ | 7.08M | +23.8% | $8.78M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passief) | 3.83M | +1.0% | $4.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passief) | 3.83M | +1.0% | $4.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 3.68M | -8.8% | $4.56M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 3.68M | -8.8% | $4.56M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Millennium Management ✦ | 3.39M | +125.6% | $4.20M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 3.38M | +109.7% | $4.20M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 24 | Renaissance Technologies ✦ | 2.89M | +73.3% | $3.59M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | State Street Global Advisors ✦ (passief) | 2.76M | +1.2% | $3.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 1.85M | +2199.0% | $2.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 1.85M | +2199.0% | $2.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 1.85M | +2199.0% | $2.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 1.85M | +2199.0% | $2.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 1.85M | +2199.0% | $2.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 1.82M | — | $2.25M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 40 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 41 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 42 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 43 | Morgan Stanley ✦ | 1.30M | — | $1.61M | 0.0% | n/c | 1 | SEC ↗ |
| 44 | Goldman Sachs Group ✦ | 1.20M | — | $1.49M | 0.0% | n/c | 1 | SEC ↗ |
| 45 | Goldman Sachs Group ✦ | 1.20M | — | $1.49M | 0.0% | n/c | 1 | SEC ↗ |
| 46 | Fidelity (FMR) ✦ | 710.96K | -27.7% | $881,591 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 47 | Fidelity (FMR) ✦ | 710.96K | -27.7% | $881,591 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 48 | D. E. Shaw & Co. ✦ | 463.90K | Nieuw | $575,234 | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| D. E. Shaw & Co. | $575,234 | 0.0% |
Verlaten
| Capital World Investors | $12.60M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 207 houders, 182.71M aandelen, $425.90M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Aug 21
Douglas Earl Martin
Officer · 29.70K aand · $62,958
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie
Aug 14
SC 13G/A — Frazier Life Sciences Public Fund, L.P.
Aug 07
SC 13G — STATE STREET CORP
Aug 07
SC 13G/A — Belldegrun Arie
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API